JP2016502844A - アノイキス抵抗性胎盤幹細胞及びその使用 - Google Patents

アノイキス抵抗性胎盤幹細胞及びその使用 Download PDF

Info

Publication number
JP2016502844A
JP2016502844A JP2015547970A JP2015547970A JP2016502844A JP 2016502844 A JP2016502844 A JP 2016502844A JP 2015547970 A JP2015547970 A JP 2015547970A JP 2015547970 A JP2015547970 A JP 2015547970A JP 2016502844 A JP2016502844 A JP 2016502844A
Authority
JP
Japan
Prior art keywords
ncbi gene
placental stem
gene
anoikis
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015547970A
Other languages
English (en)
Japanese (ja)
Inventor
ズハング キアオクイ
ズハング キアオクイ
アボット スチュアート
アボット スチュアート
ボスキナリアン‐ベルセ バネッサ
ボスキナリアン‐ベルセ バネッサ
Original Assignee
アントフロゲネシス コーポレーション
アントフロゲネシス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アントフロゲネシス コーポレーション, アントフロゲネシス コーポレーション filed Critical アントフロゲネシス コーポレーション
Publication of JP2016502844A publication Critical patent/JP2016502844A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2015547970A 2012-12-14 2013-12-13 アノイキス抵抗性胎盤幹細胞及びその使用 Pending JP2016502844A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737498P 2012-12-14 2012-12-14
US61/737,498 2012-12-14
PCT/US2013/074892 WO2014093753A1 (en) 2012-12-14 2013-12-13 Anoikis resistant placental stem cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018224316A Division JP2019068814A (ja) 2012-12-14 2018-11-30 アノイキス抵抗性胎盤幹細胞及びその使用

Publications (1)

Publication Number Publication Date
JP2016502844A true JP2016502844A (ja) 2016-02-01

Family

ID=50934980

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015547970A Pending JP2016502844A (ja) 2012-12-14 2013-12-13 アノイキス抵抗性胎盤幹細胞及びその使用
JP2018224316A Pending JP2019068814A (ja) 2012-12-14 2018-11-30 アノイキス抵抗性胎盤幹細胞及びその使用
JP2020185486A Withdrawn JP2021045133A (ja) 2012-12-14 2020-11-06 アノイキス抵抗性胎盤幹細胞及びその使用
JP2022112849A Pending JP2022160451A (ja) 2012-12-14 2022-07-14 アノイキス抵抗性胎盤幹細胞及びその使用
JP2024105938A Pending JP2024153631A (ja) 2012-12-14 2024-07-01 アノイキス抵抗性胎盤幹細胞及びその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018224316A Pending JP2019068814A (ja) 2012-12-14 2018-11-30 アノイキス抵抗性胎盤幹細胞及びその使用
JP2020185486A Withdrawn JP2021045133A (ja) 2012-12-14 2020-11-06 アノイキス抵抗性胎盤幹細胞及びその使用
JP2022112849A Pending JP2022160451A (ja) 2012-12-14 2022-07-14 アノイキス抵抗性胎盤幹細胞及びその使用
JP2024105938A Pending JP2024153631A (ja) 2012-12-14 2024-07-01 アノイキス抵抗性胎盤幹細胞及びその使用

Country Status (7)

Country Link
US (1) US20150307879A1 (cg-RX-API-DMAC10.html)
EP (2) EP2938196B1 (cg-RX-API-DMAC10.html)
JP (5) JP2016502844A (cg-RX-API-DMAC10.html)
CN (2) CN113481164A (cg-RX-API-DMAC10.html)
AU (1) AU2013359076A1 (cg-RX-API-DMAC10.html)
CA (1) CA2895106C (cg-RX-API-DMAC10.html)
WO (1) WO2014093753A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512433A (ja) * 2013-03-14 2016-04-28 アントフロゲネシス コーポレーション 増強胎盤幹細胞及びその使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107475419A (zh) * 2017-09-22 2017-12-15 浙江大学 Kndc1基因及其表达产物在卵巢癌检测中的应用
CN110129321B (zh) * 2019-07-08 2021-10-15 江苏医药职业学院 降低LSG1基因表达的siRNA、重组载体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521929A (ja) * 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞集団

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
WO2000063268A1 (en) 1999-04-16 2000-10-26 Wm. Marsh Rice University Poly(propylene fumarate) cross linked with poly(ethylene glycol)
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
MXPA03005014A (es) 2000-12-06 2004-09-10 Robert J Hariri Metodo para recolectar celulas madres de la placenta.
EP2338983B1 (en) 2001-02-14 2015-10-07 Anthrogenesis Corporation Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
AU2002251935B2 (en) 2001-02-14 2007-11-29 Celularity Inc. Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
EP1957633B1 (en) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
US9598669B2 (en) 2005-12-29 2017-03-21 Anthrogenesis Corporation Composition for collecting placental stem cells and methods of using the composition
US20100305188A1 (en) * 2007-10-03 2010-12-02 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of regulating the proliferation of cell
CN101862315A (zh) * 2009-04-17 2010-10-20 中国医学科学院血液病医院（血液学研究所） 双取代苯基双胍诱导恶性肿瘤细胞失巢凋亡的用途
EP2494076B1 (en) * 2009-10-26 2017-11-22 Abbott Molecular Inc. Detection of chromosomal abnormalities associated with prognosis of non small cell lung cancer
LT2494039T (lt) * 2009-10-31 2019-07-25 Genesis Technologies Limited Ląstelių perprogramavimo būdai ir jų panaudojimas
PL2556145T3 (pl) 2010-04-07 2017-02-28 Anthrogenesis Corporation Angiogeneza z zastosowaniem łożyskowych komórek macierzystych
AR084754A1 (es) * 2010-12-30 2013-06-05 Anthrogenesis Corp Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso
US8969315B2 (en) * 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
WO2014159806A1 (en) * 2013-03-14 2014-10-02 Anthrogenesis Corporation Enhanced placental stem cells and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521929A (ja) * 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞集団

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512433A (ja) * 2013-03-14 2016-04-28 アントフロゲネシス コーポレーション 増強胎盤幹細胞及びその使用

Also Published As

Publication number Publication date
NZ709113A (en) 2020-11-27
JP2019068814A (ja) 2019-05-09
EP3556215A1 (en) 2019-10-23
EP2938196A1 (en) 2015-11-04
US20150307879A1 (en) 2015-10-29
EP2938196B1 (en) 2019-04-03
CN105283075A (zh) 2016-01-27
WO2014093753A1 (en) 2014-06-19
EP2938196A4 (en) 2016-10-26
CA2895106A1 (en) 2014-06-19
JP2021045133A (ja) 2021-03-25
CA2895106C (en) 2023-01-24
CN113481164A (zh) 2021-10-08
JP2022160451A (ja) 2022-10-19
AU2013359076A1 (en) 2015-07-02
JP2024153631A (ja) 2024-10-29

Similar Documents

Publication Publication Date Title
US8969315B2 (en) Enhancement of placental stem cell potency using modulatory RNA molecules
JP2022166249A (ja) ヒト胎盤灌流液由来の血管形成細胞
JP5469457B2 (ja) 胎盤幹細胞を使用する腫瘍抑制
CN101395266B (zh) 胎盘干细胞群
US20230081199A1 (en) Enhanced placental stem cells and uses thereof
JP2024153631A (ja) アノイキス抵抗性胎盤幹細胞及びその使用
CN101631852A (zh) 用胎盘细胞群治疗骨缺损的方法和组合物
HK40013725A (en) Anoikis resistant placental stem cells and uses thereof
US20220235326A1 (en) Enhancement of fibroblast therapeutic activity by rna
HK40051320A (en) Enhanced placental stem cells and uses thereof
NZ709113B2 (en) Anoikis resistant placental stem cells and uses thereof
CN101326280A (zh) 使用胎盘干细胞的免疫调节
HK1139707A (en) Methods and compositions for treatment of bone defects with placental cell populations

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180731